Molecular Partners Ag ADR (MOLN)

$MOLN pt 4.4

$GTBP $ALXO $ERAS $MOLN $SLDB

$MOLN Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 Molecular Partners and Orano Med have nominated MP0726, a Radio-DARPin targeting mesothelin (MSLN), for development under their strategic partnership. Designed for the treatment of ovarian cancer, MP0726 has shown promising in vivo tumor accumulation, selective MSLN binding, and a favorable tumor-to-kidney ratio. Preclinical data will be presented at the 2025 SNMMI Annual Meeting in New Orleans.

$MOLN $MOLN news, maybe add to monday watchlist.

🚀 Hot IND Filings Ahead! 🚀 Watch these biotech plays gearing up for IND filings in H1 & Mid-2025: • $GTBP GTB-5550 (solid tumors) – PoA 10% • $ALXO ALX2004 (EGFR ADC) – PoA 25% • $ERAS ERAS-0015 (NRAS melanoma) – PoA 12% • $MOLN MP0712 (DLL3 target) – PoA 12% • $SLDB SGT-501 (gene therapy for CPVT) – PoA 30% Early-stage catalysts worth tracking for potential moves! Get full details & real-time updates at biopharmawatch.com #Biotech #INDFilings #Catalysts #BiotechInvesting

$MOLN Molecular Partners to preent updated data from MP0533 trial at EHA congress Molecular Partners announced a poster presentation with updated data from a Phase 1/2a trial of the tetraspecific T-cell engager MP0533 in relapsed/refractory acute myeloid leukemia, at the 30th European Hematology Association Congress, taking place in Milan on June 12-15. The poster outlines the impact of accelerated step-up dosing regimen of MP0533 on exposure and clinical responses in cohort 8, providing the rationale for further optimization to the dosing regimen implemented in the ongoing cohort 9. Data from cohort 8 show that 3 of 8 evaluable patients achieved a clinical response after the first cycle, with one patient achieving a complete response and two patients a complete response with partial hematologic recovery as best overall response. Two patients maintained a response for more than 3 months and one patient remains on treatment, maintaining a response beyond 6 months at the time of data cutoff. Cohort 8 implemented a higher starting dose than cohorts 1-7, and the inclusion of an additional day of dosing, reaching the target dose by day 12, as opposed to day 15 previously. Cohort 8 data indicate that patients maintained exposure to MP0533 for a longer period of time within the predicted therapeutic range through the accelerated step-up dosing scheme, within the first cycle. Data show that patients reached over 4 days of relevant exposure, with 5 out of 8 patients displaying greater than 50% blast reduction. MP0533 shows an acceptable safety profile after adjustment of the target dose in cohort 8. In cohorts 1-7, where step-up dosing reached target dose by day 15, exposure to predicted therapeutic doses was limited to roughly 2 days in the first cycle, most likely due to target-mediated-drug deposition. This prior treatment protocol, despite demonstrating initial blast reductions in ~30% of patients, resulted in limited responses. Based on the encouraging antitumor activity observed in cohort 8, the amended protocol for cohort 9 and beyond includes further acceleration of the step-up dosing to reach therapeutically-relevant doses faster, increased frequency of dosing for higher cumulative MP0533 exposure, and the introduction of anti-CD20 premedication to mitigate loss of exposure, with the objective to further increase the depth and duration of responses in patients. Cohort 9 is currently dosing patients and initial data from the amended dosing scheme are expected in H2 2025. Additionally, future study cohorts will evaluate the combination of azacitidine/venetoclax with MP0533.

$MOLN https://prismmarketview.com/molecular-partners-cuts-costs-extends-cash-runway-into-2028-while-advancing-key-clinical-programs/

$MOLN stockholders filed a claim against Molecular Partners for overstating the clinical prospects of its COVID-19 treatment, leading to major losses after trial results failed. You can join this case to be notified about potential recovery: https://11th.com/cases/191

$MOLN Big exposure at 3 oncology conferences this upcoming week, do your dd research

🌅🌅watchlist watchlist: ✅️ $INEO mid 1.50 support, if above 2, have potential to 2.30/50 ✅️ $GLMD low 2 support, if above 2.60, have potential to 2.9/3, ✅️ $AMPY low 3 support, if above 3.60, have potential to 3.80/.90, ends merger with Juniper Capital ✅️ $MOLN low 4 support, if above 4.50 have potential to 4/4.30, ✅️ $GOVX low 1 support, if above 1.20, have potential to 1.40/.50, 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🚨🚨 🎯 🎯 Ideal long stop loss if below current support 🚫🚫 Avoid chasing long into strength near resistance. ✅️ ADTX still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D